Portal de recerca
Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia
Autors de IIS La Fe
Autors aliens a IIS La Fe
- Elena C
- Galli A
- Such E
- Meggendorfer M
- Germing U
- Rizzo E
- Cervera J
- Molteni E
- Fasan A
- Schuler E
- Ambaglio I
- Zibellini S
- Kuendgen A
- Travaglino E
- Sancho-Tello R
- Catricala S
- Vicente AI
- Haferlach T
- Haferlach C
- Sanz GF
- Malcovati L
- Cazzola M
Abstract
Chronic myelomonocytic leukemia (CMML) is a myelodysplastic/myeloproliferative neoplasm with variable clinical course. To predict the clinical outcome, we previously developed a CMML-specific prognostic scoring system (CPSS) based on clinical parameters and cytogenetics. In this work, we tested the hypothesis that accounting for gene mutations would further improve risk stratification of CMML patients. We therefore sequenced 38 genes to explore the role of somatic mutations in disease phenotype and clinical outcome. Overall, 199 of 214 (93%) CMML patients carried at least 1 somatic mutation. Stepwise linear regression models showed that these mutations accounted for 15% to 24% of variability of clinical phenotype. Based on multivariable Cox regression analyses, cytogenetic abnormalities and mutations in RUNX1, NRAS, SETBP1, and ASXL1 were independently associated with overall survival (OS). Using these parameters, we defined a genetic score that identified 4 categories with significantly different OS and cumulative incidence of leukemic evolution. In multivariable analyses, genetic score, red blood cell transfusion dependency, white blood cell count, and marrow blasts retained independent prognostic value. These parameters were included into a clinical/molecular CPSS (CPSS-Mol) model that identified 4 risk groups with markedly different median OS (from >144 to 18 months, hazard ratio [HR] = 2.69) and cumulative incidence of leukemic evolution (from 0% to 48% at 4 years, HR = 3.84) (P<.001). The CPSS-Mol fully retained its ability to riskstratify in an independent validation cohort of 260 CMML patients. In conclusion, integrating conventional parameters and gene mutations significantly improves risk stratification of CMML patients, providing a robust basis for clinical decision-making and a reliable tool for clinical trials.
Dades de la publicació
- ISSN/ISSNe:
- 0006-4971, 1528-0020
- Tipus:
- Article
- Pàgines:
- 1408-1417
- PubMed:
- 27385790
- Factor d'Impacte:
- 5,919 SCImago ℠
- Quartil:
- Q1 SCImago ℠
Blood AMER SOC HEMATOLOGY
Cites Rebudes en Web of Science: 199
Documents
- No hi ha documents
Filiacions
Projectes associats
CARACTERIZACIÓN MOLECULAR DE FORMAS ESPECÍFICAS DE LEUCEMIA MIELOBLÁSTICA AGUDA (LMA) MEDIANTE SECUENCIACIÓN EXÓMICA COMPLETA
Investigador Principal: MIGUEL ÁNGEL SANZ ALONSO
PI12/01047 . INSTITUTO DE SALUD CARLOS III; FUNDACIÓN PARA LA INVESTIGACIÓN DEL HOSPITAL UNIVERSITARIO LA FE DE LA COMUNIDAD VALENCIANA . 2013
RED TEMATICA DE INVESTIGACION COOPERATIVA EN CANCER (RTICC)
Investigador Principal: MIGUEL ÁNGEL SANZ ALONSO
RD12/0036/0014 . INSTITUTO DE SALUD CARLOS III . 2013
ESTUDIO FASE II, MULTICÉNTRICO, ABIERTO, ALEATORIZADO PARA EVALUAR LA SEGURIDAD Y LA EFICACIA DE DOS POSOLOGÍAS DISTINTAS DE LDE225 ORAL, EN PACIENTES ADULTOS CON LEUCEMIA AGUDA REFRACTARIA/EN RECIDIVA O EN PACIENTES CON EDAD AVANZADA SIN TRATAMIENTO PREVIO.
Investigador Principal: MIGUEL ÁNGEL SANZ ALONSO
CLDE225X2203 . 2013